Related Experiment Video
Updated: Aug 22, 2026

Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
Gastrointestinal stromal tumors: a spectrum of disease
Cord Sturgeon1, Gregorio Chejfec, N Joseph Espat
1Department of Surgery, University of Illinois at Chicago, M/C 958, 840 S. Wood Street, Room 435E CSB, Chicago, IL 60612, USA.
Abstract:
The majority of gastrointestinal stromal tumors (GIST) express c-kit, a growth factor receptor with tyrosine kinase activity. Mutations in the c-kit proto-oncogene may lead to constitutive ligand-independent activation of c-kit and subsequent neoplastic transformation. Selective tyrosine kinase inhibitors target this property of GIST and have become the standard chemotherapy for metastatic or unresectable tumors. The mainstay of treatment, however, continues to be complete surgical resection. Tyrosine kinase inhibitors may prove expedient for adjuvant therapy, and are currently the focus of clinical trials conducted by the ACOSOG, RTOG, and ACRIN. It is important to distinguish GISTs from other mesenchymal tumors of the GI tract because of differences in natural history, as well as the efficacy of treatments targeting the GIST tyrosine kinase.
Insights
Gastrointestinal stromal tumors (GIST) often have c-kit mutations, driving cancer growth. Tyrosine kinase inhibitors are key treatments, alongside surgery, for advanced GIST.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the GI tract.
- Most GISTs express the c-kit receptor tyrosine kinase, a key factor in tumor development.
Observation:
- Mutations in the c-kit proto-oncogene can lead to uncontrolled activation of the receptor.
- This constitutive activation drives neoplastic transformation and tumor growth.
Findings:
- Selective tyrosine kinase inhibitors (TKIs) effectively target the activated c-kit in GIST.
- TKIs are now standard chemotherapy for metastatic or unresectable GIST.
- Complete surgical resection remains the primary treatment modality for GIST.
Implications:
- TKIs show promise as adjuvant therapy for GIST, with ongoing clinical trials.
- Accurate diagnosis of GIST is crucial to differentiate from other mesenchymal tumors due to distinct prognoses and treatment responses.
- Targeting GIST tyrosine kinase offers a specific therapeutic strategy for this malignancy.
More Related Videos
07:21Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
06:43Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Related Concept Videos
The Tumor Microenvironment
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease I: Introduction